![José Vicente Terencio](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
José Vicente Terencio
Directeur des opérations chez Gri-Cel SA
Profil
José Vicente Terencio is currently the Director at VCN Biosciences SL, Director at l'Associació Catalana d'Empreses de Biotecnologia, and Chief Operating Officer at Gri-Cel SA. Previously, he worked as a Non-Executive Director at TiGenix NV from 2013 to 2015.
He holds a doctorate degree from the University of Barcelona.
Postes actifs de José Vicente Terencio
Sociétés | Poste | Début |
---|---|---|
Gri-Cel SA
![]() Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher. | Directeur des opérations | - |
VCN Biosciences SL
![]() VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Directeur/Membre du Conseil | - |
l'Associació Catalana d'Empreses de Biotecnologia
![]() l'Associació Catalana d'Empreses de Biotecnologia Miscellaneous Commercial ServicesCommercial Services l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Anciens postes connus de José Vicente Terencio
Sociétés | Poste | Fin |
---|---|---|
TIGENIX NV | Directeur/Membre du Conseil | 31/07/2015 |
Formation de José Vicente Terencio
University of Barcelona | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 4 |
---|---|
Gri-Cel SA
![]() Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher. | Finance |
VCN Biosciences SL
![]() VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
TiGenix NV
![]() TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
l'Associació Catalana d'Empreses de Biotecnologia
![]() l'Associació Catalana d'Empreses de Biotecnologia Miscellaneous Commercial ServicesCommercial Services l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain. | Commercial Services |